In-Vitro Fertilization Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technique (ICSI IVF, Non-ICSI/ Traditional IVF), By Product (IVF Culture Media, ICSI Machine, IVF Incubators, Cryo-System, Others), By Egg Donor (Frozen Non-donor, Fresh Non-donor, Frozen Donor, Fresh Donor), By Infertility (Male, Female), By Application (Fertility Clinics, Hospitals, Others) By Region & Competition, 2020-2030F

Market Overview

Global In-Vitro Fertilization Market was valued at USD 28.41 billion in 2024 and is expected to reach USD 40.87 billion by 2030 with a CAGR of 6.25% during the forecast period. This growth is accounted for by increasing infertility rates, advancements in IVF technology, and a growing trend towards delaying childbirth. In-vitro fertilization (IVF) is a medical procedure that involves fertilizing an egg with sperm outside the body in a laboratory dish and then transferring the embryo to the uterus. It is a widely used assisted reproductive technology (ART) that has helped millions of couples worldwide to conceive. Infertility rate has been increasing globally. This is one of the key factors driving the growth of the IVF market. Several factors, including lifestyle changes, pollution, and an increase in age-related infertility, have contributed to the rising infertility rates.

Key Market Drivers

Rising Infertility Rates Globally

One of the most significant drivers of the global IVF market is the increasing prevalence of infertility, which affects millions of individuals and couples worldwide. According to the World Health Organization (WHO), approximately one in six people globally experience infertility in their lifetime. This rise in infertility can be attributed to a multitude of factors, including delayed parenthood due to career priorities, stress, lifestyle choices, obesity, smoking, and environmental toxins. In women, age remains a critical factor, with fertility declining significantly after age 35. Additionally, men’s sperm quality has also shown declining trends globally, contributing equally to the issue.

Government bodies in many countries are acknowledging this growing concern by offering support to those undergoing fertility treatments. Several European nations, for example, provide partial or full reimbursement for IVF cycles. Furthermore, increased awareness campaigns by public health agencies and non-governmental organizations (NGOs) are making IVF more accessible and socially accepted treatment. The growing middle class in emerging economies, combined with increased health insurance penetration and improving healthcare infrastructure, is making assisted reproductive technologies more accessible to the public, thus propelling market growth.

Advancements in Assisted Reproductive Technologies (ART)

The IVF market is also strongly driven by advancements in assisted reproductive technologies and laboratory practices. Innovations such as intracytoplasmic sperm injection (ICSI), preimplantation genetic testing (PGT), time-lapse embryo imaging, and cryopreservation techniques have significantly improved IVF success rates. These advancements have reduced treatment failures and enhanced the precision and personalization of IVF procedures.

Furthermore, improvements in culture media, embryo selection techniques, and minimally invasive procedures have led to safer and more efficient fertility treatments. For example, the development of vitrification for egg and embryo freezing has improved survival rates post-thaw, increasing the chances of a successful pregnancy even years after the initial retrieval. Public and private research funding and collaborations between biotechnology firms and academic institutions have also accelerated the pace of innovation in this space.

Regulatory support has played a critical role in ensuring that these innovations are implemented responsibly. For instance, in the U.S., the Centers for Disease Control and Prevention (CDC) actively collects and publishes data on ART outcomes, promoting transparency and informed decision-making. These technological strides not only enhance clinical outcomes but also attract a wider population to opt for IVF treatments, thus expanding the market.

Download Free Sample Report

Key Market Challenges

High Cost of Treatment and Limited Accessibility

Despite technological advancements and rising demand, the high cost of IVF treatment remains a major barrier to market expansion, especially in low- and middle-income countries. IVF procedures can cost thousands of dollars per cycle, with no guarantee of success, making them unaffordable for many people. The financial burden becomes even more pronounced when multiple cycles are required.

While some governments and insurance providers cover IVF treatments partially, the lack of universal coverage and varying reimbursement policies limit accessibility. In countries like the U.S., fertility treatments are often considered elective and are not covered under standard insurance plans. In contrast, countries like Israel and parts of Europe provide extensive public funding for fertility treatments, which contributes to higher utilization rates.

Additionally, the lack of IVF centers in rural or underdeveloped regions poses another barrier, forcing patients to travel long distances to access care. The situation underscores a significant disparity in access to reproductive healthcare based on socioeconomic status and geography. Policymakers need to address this inequality through subsidies, expanded insurance coverage, and infrastructure development to ensure that IVF treatments become accessible to a broader population segment.

Ethical, Legal, and Cultural Concerns

Ethical and legal issues continue to present significant challenges for the global IVF market. Societal perceptions about assisted reproductive technologies differ widely across regions, influenced by religious, cultural, and legal factors. In some countries, the use of donor gametes, surrogacy, or embryo selection is heavily regulated or banned, limiting the full application of IVF technologies.

For example, countries in the Middle East and some Asian regions have strict religious or cultural reservations about sperm or egg donation and surrogacy. This impacts patient choice and creates a complex legal environment for fertility providers. Moreover, the growing use of techniques like gene editing or selecting embryos based on genetic markers has sparked debates around the ethical boundaries of reproductive technology.

Governments and regulatory bodies are often slow to update laws in response to rapid scientific advances, leading to inconsistencies and uncertainties for clinics and patients alike. For instance, while the European Union has general safety regulations for ART, specific rules vary between member countries, creating a fragmented legal landscape. Addressing these issues requires balanced policymaking that respects cultural sensitivities while promoting equitable access to safe and effective fertility treatments.

Key Market Trends

Growing Acceptance of Fertility Preservation

An emerging trend in the global IVF market is the increasing demand for fertility preservation options, particularly among young adults pursuing career goals or undergoing medical treatments like chemotherapy that can impact fertility. Egg freezing, sperm freezing, and embryo freezing are gaining traction as individuals choose to delay childbearing for personal or medical reasons.

This trend is being supported by healthcare institutions and even corporate employers. Some companies have begun offering egg freezing as part of employee healthcare benefits, recognizing the importance of reproductive autonomy. Additionally, national health services in several countries are also providing fertility preservation for cancer patients as part of their treatment plans.

From a policy standpoint, various governments are integrating fertility preservation into reproductive health policies. For example, guidelines from the American Society of Clinical Oncology (ASCO) emphasize fertility preservation discussions with patients before cancer treatment begins. As awareness grows and societal taboos surrounding assisted reproduction continue to diminish, demand for IVF services is increasing even among healthy individuals seeking future reproductive flexibility. This broadens the user base for IVF beyond traditional infertility patients, positioning the market for sustained long-term growth.

Cross-Border Reproductive Care and Fertility Tourism

The rise of cross-border reproductive care, often referred to as fertility tourism, is another significant trend in the IVF market. Individuals and couples from countries with strict IVF regulations or high treatment costs are increasingly traveling to destinations that offer affordable and legally accessible fertility services. Countries such as India, Thailand, Greece, and Spain have emerged as popular hubs for medical tourists seeking IVF due to their cost-effectiveness, availability of advanced technology, and experienced medical personnel.

This trend is supported by globalization, increased international mobility, and growing digital access to information about medical facilities abroad. Many IVF clinics in these countries cater specifically to international patients, offering package deals, concierge services, and multilingual support. Governments in these regions are also recognizing the economic benefits and are investing in medical infrastructure and regulatory frameworks to support ethical medical tourism. For instance, the Indian government has introduced the Assisted Reproductive Technology (Regulation) Act to monitor and regulate ART services while promoting responsible practices. Fertility tourism not only expands the reach of IVF services but also fosters global competition, pushing clinics to maintain high standards of care and innovate continuously.

Segmental Insights

Egg Donor Insights

Based on Egg Donor, the frozen non-donor emerged as the largest revenue contributor in the IVF market. This dominance is primarily attributed to the cost-effectiveness of frozen non-donor procedures when compared to fresh non-donor cycles, as well as the comparatively less invasive nature of the frozen process. These procedures allow for better scheduling flexibility, improved implantation success rates due to optimized endometrial receptivity, and lower health risks associated with ovarian hyperstimulation. Meanwhile, the fresh donor segment is anticipated to witness notable growth throughout the forecast period. According to the 2020 National ART Summary Report, approximately 1,477 assisted reproductive technology (ART) cycles in the United States utilized fresh donor eggs, with a promising 53.9% of transfers resulting in live births. These success rates continue to drive patient interest and clinical adoption of fresh donor cycles, particularly for individuals or couples facing severe infertility challenges.

Download Free Sample Report

Regional Insights

Based on the region, North America held the largest share of the global In-Vitro Fertilization market. This dominance can be attributed to a combination of factors including advanced healthcare infrastructure, a high level of awareness about fertility treatment options, and widespread availability of cutting-edge reproductive technologies. The region benefits from the presence of numerous specialized fertility clinics and leading research institutions that drive innovation in procedures such as in-vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), and preimplantation genetic testing (PGT).

In the United States and Canada, regulatory frameworks support the practice and expansion of ART services, with several states offering insurance coverage or reimbursement for fertility treatments, making them more accessible to a broader patient base. Moreover, the trend of delayed parenthood, influenced by career priorities and lifestyle choices, has contributed to a higher demand for fertility preservation and treatment options. Technological advancements in cryopreservation, embryo culture, and lab automation have also supported North America's leadership position in the market.

Recent Developments

• In November 2024, India IVF secured $1.25 million in pre-Series A funding from Tomorrow Capital, marking its first external investment. This funding aims to enhance fertility care access in underserved North Indian regions through a tech-enabled platform offering comprehensive services. With the help of this new funding, India IVF will be able to expand throughout North India and close important access gaps to fertility care.
• In August 2024, Birla Fertility & IVF (BFI), a Gurgaon-based company, declared its intention to open eight to twelve new centers across South and West India by FY25. The fertility care business announced its foray into Tamil Nadu, Maharashtra, and Karnataka with the purchase of 12 BabyScience IVF clinics.
• In July 2024, Mira, a leading hormonal health company based in the United States, unveiled an online clinic aiming to provide personalized support to people struggling to conceive from fertility professionals. It focuses on balancing hormones, enhancing nutrition and gut health, establishing effective exercise routines, and boosting mental well-being.
• In May 2024, Gameto, a biotechnology company focused on developing new treatment options for women's health, closed an oversubscribed USD 33 Million Series B investment round, with participation from existing investors, including Insight Partners, Future Ventures, and BOLD Capital Partners led by Two Sigma Ventures with RA Capital. In the United States, funding will be provided to finish the clinical development of Fertilo-their novel investigational in vitro maturation solution of engineered OSCs to mature eggs outside of the body.

Key Market Players

• The Fertility Center of Las Vegas
• Overlake Reproductive Health
• Gennet City Fertility
• Zita West Clinic
• Fertility Plus Clinic
• Nova IVF Centre and Fertility Clinic
• Bloom IVF Centre
• Progenesis Fertility Center
• Medicana IVF Center
• Medical Park Hospitals
• ART Fertility Clinics

Report Scope:

In this report, the Global In-Vitro Fertilization Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• In-Vitro Fertilization Market, By Technique:

o   ICSI IVF

o   Non-ICSI/ Traditional IVF

• In-Vitro Fertilization Market, By Product:

o   IVF Culture Media

o   ICSI Machine

o   IVF Incubators

o   Cryo-System

o   Others

• In-Vitro Fertilization Market, By Egg Donor:

o   Frozen non-donor

o   Fresh non-donor

o   Frozen Donor

o   Fresh Donor

• In-Vitro Fertilization Market, By Infertility:

o   Male

o   Female

• In-Vitro Fertilization Market, By Application:

o   Fertility Clinics

o   Hospitals

o   Others

• In-Vitro Fertilization Market, By Region:

o   North America

§  United States

§  Mexico

§  Canada

o   Europe

§  France

§  Germany

§  United Kingdom

§  Italy

§  Spain

o   Asia-Pacific

§  China

§  India

§  South Korea

§  Japan

§  Australia

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East and Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global In-Vitro Fertilization Market.

Available Customizations:

Global In-Vitro Fertilization Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global In-Vitro Fertilization Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]